ID
22207
Descripción
Study part: 60 Day Post- Treatment Serious Adverse Events. A phase III multinational, randomized, single-blind study of recombinant humanized anti-p185HER2 monoclonal antibody (rhuMAb HER2) in patients with HER2/neu overexpression who have not received prior cytotoxic chemotherapy for metastatic breast cancer. "Terms of use: You may not use this document or the information contained herein to a regulatory authority in connection with an application for a marketing authorization or any other regulatory submission without the express written consent of Roche"
Palabras clave
Versiones (1)
- 23/5/17 23/5/17 -
Titular de derechos de autor
Roche
Subido en
23 de mayo de 2017
DOI
Para solicitar uno, por favor iniciar sesión.
Licencia
Creative Commons BY-NC 3.0
Comentarios del modelo :
Puede comentar sobre el modelo de datos aquí. A través de las burbujas de diálogo en los grupos de elementos y elementos, puede agregar comentarios específicos.
Comentarios de grupo de elementos para :
Comentarios del elemento para :
Para descargar modelos de datos, debe haber iniciado sesión. Por favor iniciar sesión o Registrate gratis.
60 DAY POST-TREATMENT SERIOUS ADVERSE EVENTS Roche H0650g Breast Cancer
60 DAY POST-TREATMENT SERIOUS ADVERSE EVENTS
- StudyEvent: ODM
Similar models
60 DAY POST-TREATMENT SERIOUS ADVERSE EVENTS
- StudyEvent: ODM
C0877248 (UMLS CUI [1,2])
C1519255 (UMLS CUI [1,2])
C1519255 (UMLS CUI [1,2])
C0304229 (UMLS CUI [1,2])
C0013227 (UMLS CUI [1,2])
C0543467 (UMLS CUI [1,2])
C0205394 (UMLS CUI [1,2])
C1710066 (UMLS CUI [1,2])
C1710066 (UMLS CUI [1,2])
C1710066 (UMLS CUI [1,2])
C1710066 (UMLS CUI [1,2])
C1710066 (UMLS CUI [1,2])